EIRPET FLEA & TICK COLLAR FOR DOGS
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
10-01-2016
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DIMPYLATE
Available from:
P.B.S Sales Limited
ATC code:
QP53AF
INN (International Name):
DIMPYLATE
Dosage:
15 %w/v
Pharmaceutical form:
Collar
Prescription type:
CAM-Companion Animal Medicine
Therapeutic group:
Canine
Therapeutic area:
Organophosphorous compounds
Therapeutic indications:
Ectoparasiticide
Authorization status:
Authorised
Authorization date:
2000-11-24
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Eirpet Flea and Tick Collar for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Collar
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dog
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of dogs with fleas (Ctenocephalides felis) and ticks (Ixodes ricinus).
4.3 CONTRAINDICATIONS
Do not use in case of known hypersensitivity to the active ingredient.
Do not use on sick and recovering dogs.
Do not use in known cases of liver disorder.
Do not use on pregnant animals.
Do not use in dogs under 6 months of age.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
Active Substance
Dimpylate
3.6 g
15
% w/w
(as stabilised diazinon at 92% diazinon)
3.913 g
16.304 % w/w
For a full list of excipients see 6.1
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 08/01/2016_
_CRN 7022791_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None known.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS.
Diazinon is an organophosphorus compound;do not handle if under medical advice not to work with
anticholinesterases.
Due to the potential risk of hypersensitivity developing in humans to diazinon, unnecessary handling of this product
should be avoided.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
An intoxication typical for organophosphorus compounds may rarely occur in sensitive individuals.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Use during pregnancy is not recommended.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Do not combine with other organophosphorus com
Read the complete document
